

EuroCVP 2018 Congress

Cardiovascular Pharmacotherapy

Tel Aviv, Israel | 13-14 May 2018

Preliminary Program as of 26 March, 2018

Sunday, 13 May, 2018

07:30-16:30 Registration

08:30-10:00 Opening Ceremony **Hall A**

08:30 TBA

09:00-10:30 **S2: New Targets and New Therapeutic Strategies in Treatment of Hypertension** **Hall A**
Joint Session with ESC Council on Hypertension
Chairpersons: Stefan Agewall, Norway, Antonio Coca, Spain

09:00 New Scientific Evidence Leading to Modify Hypertension Treatment: How to Initiate Pharmacological Treatment
Antonio Coca, Barcelona, Spain

09:20 New Antihypertensive Strategies to Improve Blood Pressure Control
Antonio Coca, Barcelona, Spain

09:40 Time to Fend Off Hypokalemia
Keld Kjeldsen, Copenhagen, Denmark

10:00 The History of Hypertension
Reuven Zimlichman, Tel Aviv, Israel

10:20 **Panel discussion:** All

10:30-11:00 *Coffee Break, Networking and Poster Viewing*

Sunday, 13 May, 2018 (Cont.)

11:00-13:00 S3: Heart Failure Update and Debate Session: Where are we in 2018? **Hall A**
Joint Session with Israel WG on Heart Failure
Chairmen: Israel Gotsman, Israel, Giuseppe Rosano, UK

- 11:00
1. Arni should be First Line Therapy in Hf Patients
 - a. Pro: **Michele Senni**, Bergamo, Italy
 - b. Con: **Yaron Hellman**, Haifa, Israel
 2. Iron Therapy Improves Outcome in Hf Patients
 - a. Pro: **Andre Keren**, Jerusalem, Israel
 - b. Con: **Claudio Ceconi**, Ferrara, Italy
 3. LV Assist Devices Should Be an Early Treatment Strategy in Heart Failure Patients
 - a. Pro: **Tal Hasin**, Jerusalem, Israel
 - b. Con: **Tuvia Ben Gal**, Petah Tikva, Israel

Panel: Offer Amir (Israel), Gianluigi Savarese (Sweden), Jean-marc Weinstein (Israel)

13:00-14:30 Lunch Break, Networking and Poster Viewing

13:30-14:30 2018 Update on Blood Cholesterol Treatment in Coronary Patients **Hall A**
Satellite Program Arranged by MSD
Chairpersons: Basil S. Lewis, Israel

- 13:30 What are the Drugs and Treatments?
Juan Tamargo, Madrid, Spain
- 13:45 Guidelines and Real-World Perspective
Heinz Drexel, Feldkirsch, Austria
- 14:00 Tailoring Therapy: Precision Medicine in Coronary Patients
Dan Atar, Oslo, Norway
- 14:15 Round Table Discussion and Summary

14:30-16:00 S4: New Frontiers in Lipid Management **Hall A**
Joint Session with the Israeli Society for Research, Prevention and Treatment of Atherosclerosis
Chairpersons: Heinz Drexel, Austria, Ronen Durst, Israel

- 14:30 New Targets for Treating LDL-C: How Low should we go and does the Mechanism Matter?
Evan Stein, Chicago, USA
- 14:50 Targeting Inflammation for Prevention of Cardiovascular Events
Yehuda Kamari, Tel Hashomer, Israel
- 15:10 Is there a Role for Diet in the Era of New Pharmacotherapy of Lipid Disorders?
Iris Shai, Ben Gurion University of the Negev, Beer Sheva, Israel
- 15:30 New Directions in Lipid Management: What is on the Horizon?
Eran Leitersdorf, Jerusalem, Israel
- 15:50 **Panel Discussion**

16:00-16:30 Coffee Break, Networking and Poster Viewing

Sunday, 13 May, 2018 (Cont.)

16:30-18:00 S5: New Drugs for Myocardial and Pericardial Diseases: Case Based Approach **Hall A**
Joint Session with ESC and Israel WG on Myocardial and Pericardial Disease
Chairpersons: Yehuda Adler, Israel, Stefan Agewall, Norway

16:30 Diagnostic and Therapeutic Challenges in ATTR Amyloidosis
Michael Arad, Sheba Medical Center, Tel Hashomer, Israel

16:50 Fabry Disease and the Israeli Experience with Enzyme Replacement Therapy
Gheona Altarescu, Shaarei Zedek Medical Center, Jerusalem, Israel

17:10 Role of Disopyramide in Patients with HOCM – Reevaluation and new Data
Daniel Monakier, Rabin Medical Center, Petah Tikvah, Israel

17:30 Novel Immunotherapy in Idiopathic Recurrent Pericarditis: Use of IL-1 Receptor Antagonist
Dor Lotan, Sheba Medical Center, Tel Hashomer, Israel

18:00 Annual General Meeting of the ESC Working group on Cardiovascular Pharmacotherapy

18:00-19:00 Get Together Reception

Monday, 14 May, 2018

08:30-10:00 S6: New Advance in Management of Diabetes: What the Cardiologist Needs to Know **Hall A**
Chairpersons: Alexander Niessner, Austria, Thomas Schmidt, Denmark

08:30 Mechanisms of Action of Anti-Glycemic Drugs: Viewpoint of a Pharmacologist
Thomas Walther, Cork, Ireland

08:50 How to Manage Diabetes in the Patient at Risk for Heart Failure
Heinz Drexel, Feldkirch, Austria

09:10 How to Reduce Acute Cardiovascular Events in Patients with Diabetes
Yoseph Rozenman, Tel Aviv, Israel

09:30 What's on the Horizon for the Management of the Diabetic Patient? Viewpoint of a Diabetologist
Itamar Raz, Jerusalem, Israel

09:50 **Panel and conclusions**

10:00-10:30 Coffee Break, Networking and Poster Viewing

10:30-11:30 S7: Intersociety Opinion: New Drugs and Therapies **Hall A**
Joint Session with International Society of Cardiovascular Pharmacotherapy (ISCP)
Chairpersons: Augusto Gallino, Switzerland, Juan Carlos Kaski, UK, Keld Kjeldsen, Denmark

10:30 Anti-Thrombotic and Anti-Platelet Therapy after PCI in Patients with AF and CAD
Antoni Martínez-Rubio, Barcelona, Spain

10:50 Pharmacological Treatment of Diastolic Dysfunction: Present and Future Directions
Koj Hasegawa, Kyoto, Japan

11:10 Lipid Lowering Therapy in 2018: Where are we now?
Heinz Drexel, Feldkirch, Austria

Monday, 14 May, 2018 (Cont.)

11:30-13:00 S8: Critical Issues in Antithrombotic Therapy: 2018 Update **Hall A**
Joint Session with ESC Working Group on Thrombosis
Chairpersons: Joao Morais, Portugal, Christian Torp-Pedersen, Denmark

11:30 Dual Pathway (Anticoagulant/antiplatelet) Versus Dual Antiplatelet Therapy for CV Protection
Joao Morais, President, Portuguese Society of Cardiology, Leiria Hospital Center, Leiria, Portugal

11:45 Individualized DAPT Approach - Which Drug and for how Long?
Sven Wassmann, University of the Saarland, Homburg/Saar, Germany

12:00 Mechanisms of Action of the P2Y12 Inhibitor Ticagrelor in Patients with Cardiovascular Disease
Yochai Birnbaum, Baylor College of Medicine, Houston TX

12:15 Antithrombotic Therapy in Patients with AF and ACS/PCI.
Andrea Rubboli, Ospedale Maggiore, Bologna, Italy

12:30 How to Handle Bleeding and how to Use Reversal Agents
Alexander Niessner, University of Vienna, Vienna, Austria

13:00-14:00 Lunch Break, Networking and Poster Viewing

13:30-14:30 Improving Cardiovascular Outcome in Patients with Diabetes **Hall A**
Satellite program organized by Novo Nordisk
Chairpersons: TBD

13:30 Cardiovascular Outcomes as a Centerpoint of Diabetic Management
TBD

13:45 The New Promise of the GLP-1 Analogues on Clinical Outcome in Diabetic Patients
Linda Mellbin, MD, PhD, Karolinska University Hospital, Stockholm, Sweden

14:15 **Panel Discussion**

14:00-14:20 S9: Antithrombotic Therapy (cont) **Hall A**
Sponsored by Pfizer

08:30 **TBA**

14:20-15:30 S10: Challenging Clinical Cases from the Cardiovascular Pharmacotherapists **Hall A**
and Trialists of Tomorrow (CPPTs)
Chairmen: Basil Lewis, Israel, Uri Landes, Israel, Gianluigi Savarese, Sweden

14:20 Permanent Atrial Fibrillation with a CHADS-VASC Score of 1: Nothing, Aspirin or Anticoagulate?
Patrick Sulzgruber, Vienna, Austria

14:40 Triple vs. Dual Therapy in Patients with Atrial Fibrillation Following PCI - a Moving Target
Emanuel Harari, Petach Tikva, Israel

15:00 Yet Another Challenge for the Oncological Patient
Ady Orbach, Haifa, Israel

Monday, 14 May, 2018 (Cont.)

14:00-15:30	S13: Temporal Trends, Treatments and Outcome after ACS in Israel: An Update from the Israel National ACSIS Project Joint Session with the Israel WG for Acute Cardiac Care Chairpersons: Zaza Iakobishvili, Israel, Other (TBD)	Hall B
--------------------	---	---------------

14:00 Long-Term Outcome Trends in ACS Patients with Diabetes and Smoking
Ilan Goldenberg, Sheba Medical Center, Tel Hashomer, Israel

14:20 Outcome after ACS in Patients with Peripheral Arterial Disease
Shlomi Matetzky, Sheba Medical Center, Tel Hashomer, Israel

14:40 Quality Indicators in ACS: International Comparison (ACSIS and MINAP)
Zaza Iakobishvili, Rabin Medical Center, Petah Tikva, Israel

15:00 Antiplatelet and Anti-Lipid Treatment Trends: Lessons from ACSIS
Shmuel Gottlieb, Shaarei Zedek Medical Center, Jerusalem, Israel

15:20 **Panel Discussion**

15:30-16:00	<i>Coffee Break, Networking and Poster Viewing</i>
--------------------	---

16:00-17:30	TBA	Hall A
--------------------	------------	---------------

EuroCVP 2018 Congress

Cardiovascular Pharmacotherapy

Tel Aviv, Israel | 13-14 May 2018

ALL ABOUT CLINICAL TRIALS

13th & 14th May 2018
Tel Aviv, Israel

The European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy is proud to be delivering an engaging and interactive 2-day course to improve the professional knowledge and skills required to plan and deliver successful cardiovascular pharmacotherapy clinical trials.

Our goal is for all participants to leave the meeting with the improved competence and confidence to deliver better clinical trials which in turn will have a positive impact on services and patient outcomes.

This course is aimed at improving knowledge and skills related to clinical trial planning and design as well as the successful running of different types of clinical trials. We will offer interactive sessions coordinated by top experts in their fields. In addition, the course will offer highly interactive workshops on Good Clinical Practice (GCP certificate included), statistics and trial data interpretation.

At the end of the course delegates will have improved their knowledge in:

- designing and planning successful clinical trials,
- evaluating and following the correct processes and regulatory procedures,
- effectively analysing and interpreting trial data.

This course will be an excellent opportunity for education, networking and creating opportunities.

Course directors

Sven Wassmann, MD, PhD, FESC

Giuseppe MC Rosano, MD, PhD, FESC

This program is:

Organised by the ESC Working Group on Cardiovascular Pharmacotherapy

Supported by an educational grant from

Sunday, 13 May, 2018

07:30-16:30 Registration

08:45-09:00 Welcome, introduction and course objectives
S. Wassmann, G.M.C. Rosano **Hall A**

09:00-10:30 S1: All about Clinical Trials: How to Design and Run a Clinical Trial **Hall B**

09:00 An overview of the different aspects of clinical trials
A. Niessner

09:30 Planning and running a clinical trial: Site perspective
B.S. Lewis

10:00 Traditional versus novel trial designing
J. Tamargo

10:30-11:00 Coffee Break, Networking and Poster Viewing

11:00-11:40 S2: All about Clinical Trials: Regulatory Aspects **Hall B**

11:00 Requirements from regulatory agencies and post marketing surveillance
T. Walther

11:40-12:00 S3: All about Clinical Trials: The Sponsor's Viewpoint **Hall B**

11:40 The sponsor's viewpoint
TBD

12:00-13:00 S4: All about Clinical Trials: What's Next – Upcoming and Ongoing Clinical Trials **Hall B**

12:00 ACS / Antithrombotics
S. Wassmann

12:15 Lipidology
B.S. Lewis

12:30 Diabetes
H. Drexel

12:45 Heart failure
G.M.C. Rosano

13:00-14:30 Lunch Break, Networking and Poster Viewing

14:30-17:00 S5: All about Clinical Trials: Good Clinical Practice **Hall B**

14:30 GCP update for the busy clinician
D. Rolfe

16:00-16:30 Coffee Break, Networking and Poster Viewing

16:30 GCP update for the busy clinician (certificate included) (Cont)
D. Rolfe

Sunday, 13 May, 2018 (Cont.)

17:00-18:00 S6: All about Clinical Trials: How to Write a Paper and How to Publish **Hall B**

17:00 The ESC Working Group on Cardiovascular Pharmacotherapy - Perspectives of a Past-Chairman and Journal Editor-in-Chief
S. Agewall

17:15 How to write a paper and get it published
G.M.C. Rosano

18:00 Annual General Meeting of the ESC Working group on Cardiovascular Pharmacotherapy

18:00-19:00 Get Together Reception

Monday, 14 May, 2018

08:55-09:00 Welcome and objectives
S. Wassmann, G.M.C. Rosano

09:00-12:00 Workshops: Statistical Issues in Clinical Trials **Hall B**
Parallel groups (switch after 90 min)

- Randomised controlled trials and subgroup analyses - **A. Niessner**

Refreshments and networking

- Registries and meta-analyses – **G. Savarese**

10:00-10:30 Coffee Break, Networking and Poster Viewing

12:00-13:00 Workshop: How to Interpret Clinical Trial Data **Hall B**

12:00 Examples from clinical trials
S. Wassmann, Panelists

Closing remarks
G.M.C. Rosano, **S. Wassmann**

13:00-14:00 Lunch Break, Networking and Poster Viewing